Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
14 p, 4.6 MB Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases / De Mattos-Arruda, Leticia (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ; Piscuoglio, Salvatore (Institute of Pathology, University Hospital Basel) ; Gonzalez-Cao, Maria (Hospital Universitari Quirón Dexeus) ; Lim, Raymond S. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; De Filippo, Maria R. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Fusco, Nicola (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Schultheis, Anne M. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Viteri, Santiago (Hospital Universitari Quirón Dexeus) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Macedo, Gabriel S. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ; Gomez, Patricia (Vall d'Hebron Institut d'Oncologia) ; Teixidó, Cristina (Hospital Universitari Quirón Dexeus) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Vall d'Hebron Institut de Recerca) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Ramon y Cajal, Santiago (Vall d'Hebron Institut de Recerca) ; Tresserra Casas, Francesc (Hospital Universitari Quirón Dexeus) ; Weigelt, Britta (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Cortes, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630  
2.
12 p, 942.4 KB BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer / Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ; Pilotto, Sara (University of Verona (Itàlia)) ; Drozdowskyj, Ana (Pivotal (Madrid)) ; Codony-Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ; Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Gervais, Radj (Centre François Baclesse (Caen, França)) ; Massuti, Bartomeu (Hospital General de Alicante) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Majem, Margarita (Hospital de Sant Pau (Barcelona, Catalunya)) ; Felip Font, Enriqueta (Hospital Vall d'Hebron (Barcelona, Catalunya)) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ; Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ; Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ; Ramírez, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Josep Trueta, Girona. Institut Català d'Oncologia) ; Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ; De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ; López-Vivanco, Guillermo (Hospital de Cruces (Barakaldo, Biscaia)) ; Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ; Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ; Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ; Bria, Emilio (University of Verona (Itàlia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)  

See also: similar author names
2 González-Cao, María
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.